Parkinson’s Disease – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2021 To 2032


 Parkinson's disease is a chronic, progressive central nervous system disorder that belongs to a group of conditions known as motor system disorders. Parkinson's disease is caused by cell loss in the substantia nigra section of the brain. These cells produce dopamine, a chemical messenger responsible for signal transmission within the brain. Dopamine allows smooth, coordinated function of the body's muscles and movement. Thus, loss of dopamine allows neurons to fire out of control, leaving patients unable to direct or control their movement. The symptoms of Parkinson's, which often appear gradually and increase in severity over time, may include tremors or trembling, difficulty maintaining balance and gait, rigidity or stiffness of the limbs and trunk, and general slowness of movement (also called bradykinesia). Patients may also have difficulty walking, talking, or completing other simple tasks. Symptoms usually appear when between 60% and 80% of the dopamine-producing cells are damaged. Parkinson's disease affects men and women almost equally. There are no significant social, ethnic, economic, or geographic variations in disease onset.

 

The prevalence of Parkinson's disease ranges from 205 to 320 cases per 100,000 population in the USA.

 

The competitive landscape of Parkinson’s Disease includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Parkinson’s Disease across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Parkinson’s Disease Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Parkinson’s Disease – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

S. No    Asset               Company                                 Stage

1          BIIB122 Denali Therapeutics Inc. Phase 2

2          Istradefylline     Kyowa Kirin Co., Ltd.     Phase 3

3          VY-AADC02      Voyager Therapeutics    Phase 2

4          Prasinezumab   Prothena Biosciences Limited    Phase 2

5          ABBV-951         AbbVie  Phase 3

6          Mesdopetam (IRL790)   Integrative Research Laboratories AB            Phase 2

7          ANAVEX2-73    Anavex Life Sciences Corp.       Phase 2

8          Buntanetap       Annovis Bio Inc. Phase 2

9          P2B001 Pharma Two B Ltd.       Phase 3

10        TVP-1012         Takeda Phase 3

Continued

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Metabolic syndrome refers to a clustering of multiple disorders that collectively increase an individual's susceptibility to atherosclerotic cardiovascular disease, insulin resistance, diabetes mellitus, as well as vascular and neurological complications such as cerebrovascular accidents. The underlying causes of metabolic syndrome typically include excess weight, obesity, a sedentary lifestyle, and genetic predisposition. This syndrome exerts detrimental effects on various body systems. Insulin resistance, a key component of metabolic syndrome, leads to microvascular damage, increasing the risk of endothelial dysfunction, vascular resistance, hypertension, and inflammation of vessel walls. Bariatric surgery is recognized as the most effective standalone therapy for metabolic syndrome. However, patients undergoing this procedure require long-term follow-up to mitigate potential surgical, nutritional, and psychiatric complications. Thelansis’s “Metabolic Syndrome Market Outl...
Read more

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
  Type 1 Diabetes Mellitus (T1D) is characterized as an autoimmune disorder resulting in the autoimmune destruction of insulin-producing pancreatic beta cells. This condition necessitates life-long insulin replacement, administered through multiple daily insulin injections, insulin pump therapy, or an automated insulin delivery system. The absence of insulin can lead to the development of Diabetic Ketoacidosis (DKA), a life-threatening condition. The most common symptoms associated with this disease are polyuria and polydipsia. Effective management of T1D involves: Multiple daily insulin injections Insulin pump therapy An automated insulin delivery system in conjunction with glucose monitoring Continuous Glucose Monitoring (CGM) is the preferred method. However, all individuals with T1D should be capable of performing Blood Glucose Monitoring (BGM) via capillary blood if CGM is not available. Acute complications of diabetes primarily include hypo...
Read more